The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or elderly mantle cell lymphoma in Japan.
 
Kenichi Ishizawa
Honoraria - Chugai Pharma; Kyowa Hakko Kirin; Takeda
Research Funding - Celgene (Inst); Kyowa Hakko Kirin (Inst); MSD (Inst); Pfizer (Inst)
 
Michinori Ogura
Honoraria - Takeda
Consulting or Advisory Role - Celgene; Meiji Seika Kaisha; Mundipharma
 
Dai Maruyama
Honoraria - Celgene; Chugai Pharma; Eisai; Fujifilm; Janssen; Kyowa Hakko Kirin; Mochida Pharmaceutical Co. Ltd.; Mundipharma; Nippon Kayaku; Ono Pharmaceutical; Sanofi; Takeda
 
Yasunobu Abe
No Relationships to Disclose
 
Kiyoshi Ando
No Relationships to Disclose
 
Koji Izutsu
No Relationships to Disclose
 
Yasuhito Terui
No Relationships to Disclose
 
Imaizumi Yoshitaka
No Relationships to Disclose
 
Noriko Fukuhara
No Relationships to Disclose
 
Toshiki Uchida
No Relationships to Disclose
 
Ilseung Choi
No Relationships to Disclose
 
Ken Ohmachi
No Relationships to Disclose
 
Go Yamamoto
No Relationships to Disclose
 
Kensei Tobinai
Honoraria - Eisai; Mundipharma; Spectrum Pharmaceuticals; Takeda; Zenyaku Kogyo
Research Funding - Abbvie (Inst); Celgene (Inst); Chugai Pharma (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Mundipharma (Inst); Ono Pharmaceutical (Inst); SERVIER (Inst); Takeda (Inst)